Related Experiment Video

Updated: Jun 23, 2026

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
18:08

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: January 1, 2008

Genetic and environmental factors drive personalized medicine for Crohn's disease

Shigeru Oshima, Mamoru Watanabe

    The Journal of Clinical Investigation
    |October 16, 2018
    PubMed

    Insights

    Crohn

    Area of Science:

    • Gastroenterology and immunology

    Background:

    • Crohn's disease treatment is suboptimal, with unknown underlying mechanisms.
    • Anti-TNF antibody therapy has improved outcomes but not fully resolved treatment challenges.
    • Personalized treatment strategies require understanding genetic and environmental factors.

    Purpose of the Study:

    • To investigate the impact of environmental factors and genetic susceptibility on Crohn's disease pathogenesis.
    • To identify novel targets for personalized medicine in Crohn's disease treatment.

    Main Methods:

    • Analysis of environmental factors, specifically tobacco consumption.
    • Examination of the ATG16L1T300A gene mutation, a known Crohn's disease susceptibility allele.
    • Assessment of Paneth cell function in intestinal crypts.

    Main Results:

    • Tobacco consumption and the ATG16L1T300A mutation induce defects in intestinal Paneth cells.
    • These defects are observed at the bottom of the intestinal crypt, impacting cellular function.

    Conclusions:

    • Tobacco use and specific genetic variations contribute to Crohn's disease by affecting Paneth cells.
    • Targeting these factors in Paneth cells may offer new avenues for personalized Crohn's disease therapy.

    More Related Videos

    Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

    Chronic Salmonella Infection Induced Intestinal Fibrosis

    Published on: September 22, 2019

    Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

    Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

    Published on: October 14, 2025

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Pharmacogenetics and Pharmacogenomics: Overview01:29

    Pharmacogenetics and Pharmacogenomics: Overview

    Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Inflammatory Bowel Disease III: Crohn's Disease01:25

    Inflammatory Bowel Disease III: Crohn's Disease

    Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...